phrma logo

PhRMA

PhRMA Sites

Login

Explore Member-Only Resources

Access exclusive advocacy, policy, and research materials through the member site.

Login now

About

About

Our Agenda

Our Agenda

Policy Issues

We believe that patients should have access to innovative medicines.

Learn More

Innovation Ecosystem

Intellectual Property

Research & Development

Future of Medicine

Government Price Setting

International

Innovation Ecosystem

Patient Access & Affordability

PBMs & Middlemen

Hospitals and 340B

Insurance Coverage

Cost of Medicines

Medicare & Medicaid

Patient Access & Affordability

Resources

Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies.

Learn More

Resources

Resources

Newsroom

Newsroom

Blog

Blog

America's Medicines

PhRMA Foundation

PhRMA Foundation Logo

Voters for Cures

VotersForCures.org Logo

Working for Cures

workersforcures.org logo

This is Innovation

Innovation.org logo

View More

Search in PhRMA

Find resources, news, and articles related to policy issues and scientific innovation.

What are you looking for?

Most Recent

Policy Paper

Press

Blog

Report

Fact Sheet

Event

Resource

Pages

Leader

Author

Comment

/resources

About PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are laser focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. Over the last decade, PhRMA member companies have invested more than $850 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States.

Connect with PhRMA

For information on how innovative medicines save lives, please visit:  
www.PhRMA.org
www.VotersforCures.org
www.AmericasMedicines.com
www.Facebook.com/PhRMA 
www.X.com/PhRMA 

WASHINGTON, D.C. (Jan. 22, 2026) — Following hearings held today by the U.S. House Energy and Commerce Committee and the House Ways and Means Committee examining the role of health insurers in rising health care costs, Pharmaceutical Research and Manufacturers of America (PhRMA) Deputy Vice President of Media Relations Chanse Jones issued the following statement: 

“Today’s hearings showed exactly why Americans are fed up with rising insurance costs. For more than four hours, insurance executives dodged responsibility for denied care, soaring premiums and deductibles. These same companies and other entities they might own, take roughly half of every dollar spent on brand medicines, and the insurers’ own data show profits and overhead take a bigger bite out of premiums than medicines that patients need. Yet they came to the Hill offering no real transparency, accountability, or solutions. While insurers stick to the same tired playbook, our industry is working with lawmakers to deliver meaningful changes that make medicines more affordable for American patients and taxpayers.” 

Data clearly shows the largest part of the health care system — hospital care — is also the place where costs are the most out of control. The evidence:   

  • This month, CMS actuaries released their accounting of the $5.3 trillion in U.S. health care spending in 2024. Hospitals accounted for $1.6 trillion of that total, with hospital spending up by nearly 9 percent. That’s nearly one out of every three dollars spent on health care. Physicians were responsible for another $1.1 trillion.    
  • Hospital prices experienced the highest rate of increase since 2007 (up 3.4%). In contrast, CMS estimated that retail pharmaceutical prices only went up 1.4%. Net prices on pharmaceuticals have been falling for years. In 2026, even average list prices -- when adjusted for volume -- have fallen.   
  • Data continues to stack up on hospitals: The federal 340B hospital markup program grew more than 20% in 2024 to $81.4 billion, according to HRSA, making it the nation’s second-largest drug program and on pace to become the largest by 2027. Data shows 340B costs taxpayers billions each year and is rapidly growing due to large, tax-exempt hospitals exploiting the program for profit with little evidence patients are benefiting.    
  • Hospitals drive higher per capita spending in the United States compared to Europe. A KFF analysis last year concluded, “The difference in spending on inpatient and outpatient care is $4,531 per person, accounting for almost 80% of the difference in spending between the U.S. and comparable countries.”  
  • According to the insurance industry’s own data, brand medicines make up less than 10 cents of every premium dollar while hospitals take nearly half of every premium dollar. 

 

### 

Press Release

PBMs/Insurance

PhRMA Responds to Congressional Hearings with Health Insurance CEOs

January 22, 2026

Stay current on policy making

Sign up for email updates and follow us on social. 

About

Our Agenda

Policy Issues

Resources

Blog

Contact Us

Privacy Policy

Terms of Service

Facebook

Facebook

X

Twitter X

LinkedIn

LinkedIn

Instagram

instagram logo

America's Medicines

PhRMA Foundation

Voters for Cures

Working for Cures

Innovation.org

Please type your email

Success!

You've been added to the list